Back

Outcome evaluation of the association of sacubitril/valsartan and iSGLT2 in diabetic patients with heart failure with reduced ejection fraction.

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 1 - Basic Science - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Francisco Javier Camacho Jurado

Puerto Real Hospital, Puerto Real (Spain)

13 More presentations in this session

Presentation thumbnail
Elamipretide restores protein and mRNA expression levels of S100A1 in left ventricular myocardium of dogs with chronic heart failure
Professor H. Sabbah (Detroit, US)
Abstract
Presentation thumbnail
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
Miss M. Krasnova (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Introducing SGLT2 inhibitors during hospitalization. Safety and outocmes.
Doctor F. Camacho Jurado (Puerto Real, ES)
Abstract
Presentation thumbnail
Outcome evaluation of Sacubitril/Valsartan in patients with Heart Failure and reduced ejection fraction with regular follow-up meetings in a Spanish heart failure day-hospital.
Doctor F. Camacho Jurado (Puerto Real, ES)
Abstract
Presentation thumbnail
Effects of irbesartan for renal failure in the patients with chronic heart failure and preserved systolic function and atrial fibrillation

Access the full session

Session thumbnail
Poster session 1 - Basic Science - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources